Apnimed prices upsized $192m Nasdaq IPO

Apnimed has priced an upsized initial public offering of 12,000,000 shares of its common stock at $16.00 per share. The pricing defines the valuation and capital raise the company expects from its U.S. listing. The upsized deal focuses on common stock and reflects final terms agreed with the underwriting group.

Based on the offering size and price, Apnimed expects gross proceeds of $192 million before underwriting discounts, commissions and offering expenses. This figure reflects only the base 12,000,000 shares and does not include any potential proceeds from the underwriters’ option to purchase additional shares.

Apnimed has granted the underwriters a 30-day option to buy up to an additional 1,800,000 shares of common stock at the IPO price, less underwriting discounts and commissions. If exercised, this option would expand the total number of shares sold in the offering and increase the capital raised, though those incremental proceeds are not included in the $192 million expectation.

BofA Securities, Evercore ISI, Cantor and LifeSci Capital are acting as joint book-running managers for the offering. This syndicate is responsible for marketing the transaction, allocating shares to investors and stabilizing trading around the launch of the stock. Their role includes managing the over-allotment option associated with the 1,800,000 additional shares.

Apnimed common stock is expected to begin trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol APMD. The move to list on Nasdaq Global Select positions the company within one of the market’s premium tiers for equity issuers.

The offering is expected to close on or about August 3, 2026, subject to the satisfaction of customary closing conditions. Completion of the closing will finalize the capital raising process, with proceeds then available to Apnimed after deduction of underwriting and offering-related costs.

The $192 million in expected gross proceeds provides a clear indication of the scale of Apnimed’s market debut. The structure, including the potential additional 1,800,000 shares, gives the company and its underwriters flexibility to meet investor demand during the initial trading period.

With defined pricing, a set trading start date, and a named underwriter group, the company’s transition to public markets follows a conventional IPO framework. The focus now shifts to how the shares perform once trading begins under the APMD ticker on Nasdaq Global Select Market.